Status:
UNKNOWN
Hyper-CVAD Treatment in Lymphoblastic Lymphoma
Lead Sponsor:
Ajou University School of Medicine
Conditions:
Lymphoblastic Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
Treatment outcomes of lymphoblastic lymphoma (LBL) have improved by the use of the regimens for acute lymphoblastic leukemia. Hyper-CVAD is one of the most effective treatments with high remission rat...
Detailed Description
We will analyze treatment outcome of lymphoblastic lymphoma patients treated with hyper-CVAD regimen from 13 institutions in Korea. In all patients, hyper-CVAD was initial treatment. After achievement...
Eligibility Criteria
Inclusion
- age over 18 at diagnosis
- Pathologically proven lymphoblastic lymphoma
Exclusion
- proven HIV infection
- pretreatment with other regimens
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01813344
Start Date
January 1 2012
Last Update
March 19 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ajou Universtiy School of Medicine
Suwon, Kyeonggi, South Korea, 443-721